Compare SNX & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNX | RGEN |
|---|---|---|
| Founded | 1980 | 1981 |
| Country | United States | United States |
| Employees | 28500 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 8.2B |
| IPO Year | 2003 | N/A |
| Metric | SNX | RGEN |
|---|---|---|
| Price | $153.43 | $162.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 10 |
| Target Price | $168.60 | ★ $174.90 |
| AVG Volume (30 Days) | ★ 742.3K | 701.7K |
| Earning Date | 01-08-2026 | 10-28-2025 |
| Dividend Yield | ★ 1.14% | N/A |
| EPS Growth | ★ 18.98 | N/A |
| EPS | ★ 9.21 | 0.03 |
| Revenue | ★ $60,973,509,000.00 | $707,890,000.00 |
| Revenue This Year | $7.25 | $17.84 |
| Revenue Next Year | $4.50 | $12.57 |
| P/E Ratio | ★ $16.74 | $5,259.20 |
| Revenue Growth | 6.94 | ★ 11.74 |
| 52 Week Low | $92.23 | $102.97 |
| 52 Week High | $167.76 | $182.52 |
| Indicator | SNX | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 52.10 | 54.15 |
| Support Level | $147.58 | $156.01 |
| Resistance Level | $158.68 | $165.02 |
| Average True Range (ATR) | 3.35 | 4.65 |
| MACD | -0.20 | -1.07 |
| Stochastic Oscillator | 52.66 | 43.33 |
TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and data center infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include the Americas, Europe, and APJ.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.